Floatz logo

Eflornithine

Diffuse Astrocytoma

Mayo ClinicSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Diffuse Astrocytoma cohort.

Asset / SponsorPhaseRating
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
Carboplatin
Novartis Pharmaceuticals
Phase 2B
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 1/2CCC

View all 20 →

Same molecule, other indications

Eflornithine is also rated in:

classic familial adenomatous polyposisDormant
BB
Indicative ·
66 / 100
View asset →
precancerous conditionDormant
BB
Indicative ·
64 / 100
View asset →
colon adenomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →